Defunct Company
Total Trials
10
As Lead Sponsor
9
As Collaborator
1
Total Enrollment
596
NCT00363467
Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation
Phase: N/A
Role: Collaborator
Start: May 31, 2006
Completion: May 31, 2009
NCT02423122
A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)
Phase: Phase 2
Role: Lead Sponsor
Start: Apr 30, 2015
Completion: Sep 30, 2016
NCT02423200
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
Completion: Nov 30, 2016
NCT03402659
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
Start: Dec 29, 2017
Completion: Jul 31, 2019
NCT03980938
Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
Start: Jul 8, 2019
Completion: Oct 15, 2020
NCT04001517
Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies
Start: Sep 30, 2019
Completion: Jun 30, 2020
NCT05869669
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Start: May 1, 2023
Completion: Jun 16, 2025
NCT06815965
A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Start: Oct 16, 2024
Completion: Apr 30, 2026
NCT06987643
A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke
Start: Jun 20, 2025
Completion: Jun 28, 2026
NCT07033481
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
Start: Aug 31, 2025
Completion: Oct 31, 2026